Opioid Switching from Oxycodone to Morphine

Introduction to Opioid Switching

The American Thoracic Society, as published in Chest, recommends switching from oxycodone to an equivalent dose of morphine when adequate pain relief is not achieved with oxycodone, but only after proper dose titration of the initial opioid has been attempted 1, 2, 3

The European Society for Medical Oncology (ESMO) guidelines state that a different opioid should be considered in the absence of adequate analgesia despite opioid dose escalation or in the presence of unacceptable opioid side effects 2
Opioid switching should only be contemplated after adequate dose titration of oxycodone has been performed, attempts to address predictable side effects of the first-line opioid have been made, and the patient continues to experience uncontrolled pain despite dose escalation, or develops intolerable side effects 1, 2, 3

The majority of patients (50-90%) experience improvement in pain control and/or reduction in side effects after switching opioids, according to the American College of Chest Physicians, as published in Chest 1
Individual response varies remarkably from opioid to opioid due to asymmetric tolerance, different efficacies, and pharmacokinetic profiles, as noted by the European Society for Medical Oncology, published in Annals of Oncology 4

The established conversion ratio from oral oxycodone to oral morphine is 1:1.5, meaning oxycodone is 1.5 times more potent than morphine, but the calculated morphine dose should be reduced by 25-50% to account for incomplete cross-tolerance between different opioid agents, as recommended by the Centers for Disease Control and Prevention, published in MMWR Recommendations and Reports 2, 5, 6
Comprehensive assessment of the underlying clinical situation, pain and adverse effect intensity, comorbidities, concomitant drugs, and pharmacokinetic factors is required when switching opioids, according to the European Society for Medical Oncology, published in Annals of Oncology 2

Morphine carries higher risk in renal impairment compared to oxycodone, and its metabolites accumulate in renal failure, increasing toxicity risk, as noted by the American College of Chest Physicians, published in Chest 1, 3
Consider fentanyl, alfentanil, or methadone instead in patients with chronic kidney disease stages 4-5 (eGFR <30 mL/min), as recommended by the European Society for Medical Oncology, published in Annals of Oncology 2
Use additional caution and consider longer dosing intervals when prescribing to patients with hepatic dysfunction, as decreased clearance can lead to toxic accumulation, according to the Centers for Disease Control and Prevention, published in MMWR Recommendations and Reports 6

Evaluate the patient within 24-48 hours initially, then weekly during titration, and monitor for pain intensity, functional status, opioid-related adverse effects, and signs of inadequate analgesia requiring further dose adjustment, as recommended by the Centers for Disease Control and Prevention, published in MMWR Recommendations and Reports 2, 5, 6

Never switch to extended-release/long-acting morphine formulations initially—use immediate-release morphine for titration, as recommended by the Centers for Disease Control and Prevention, published in MMWR Recommendations and Reports 6
Do not use full equianalgesic conversion ratios without dose reduction—incomplete cross-tolerance is universal, according to the European Society for Medical Oncology, published in Annals of Oncology 2, 5

Consider switching to a third opioid (hydromorphone, fentanyl, or methadone) if the switch from oxycodone to morphine fails to provide adequate relief, as recommended by the European Society for Medical Oncology, published in Annals of Oncology 2, 4
Methadone should only be used by experienced clinicians due to complex pharmacokinetics, variable conversion ratios, and risk of QT prolongation, according to the European Society for Medical Oncology, published in Annals of Oncology, and the Centers for Disease Control and Prevention, published in MMWR Recommendations and Reports 4, 6